Huapyong Kang

Survival impact of repeated endobiliary radiofrequency ablation in patients undergoing durvalumab plus gemcitabine and cisplatin for extrahepatic cholangiocarcinoma (BRAVE trial): study protocol for an international multicenter randomized controlled trial

Extrahepatic cholangiocarcinoma (eCCA) often presents with unresectable disease and obstructive jaundice. Systemic therapy with gemcitabine–cisplatin plus durvalumab (GCD) is an international standard; however, the median overall survival (OS) remains about 1 year. Endobiliary ra...